Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Trulicity ® (dulaglutide)
Can Trulicity® (dulaglutide) be used in patients with impaired hepatic function?
Use Trulicity with caution in patients with impaired hepatic function. No dose adjustment is needed based on hepatic impairment.
Clinical Pharmacology Study: Impaired Hepatic Function
A phase 1, single dose, clinical pharmacology study in patients with varying hepatic impairment showed no relevant changes in the pharmacokinetics of dulaglutide.1
Compared with participants with normal hepatic function, dulaglutide systemic exposure decreased by
- 23% in patients with mild hepatic impairment
- 33% in patients with moderate hepatic impairment, and
- 21% in patients with severe hepatic impairment.1
The maximum serum concentration (Cmax) was decreased by a similar magnitude.1
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: July 30, 2021